Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2019 Jan 29;63(2):e02074-18.
doi: 10.1128/AAC.02074-18. Print 2019 Feb.

Role of Therapeutic Drug Monitoring in Treatment Optimization in Tuberculosis and Diabetes Mellitus Comorbidity

B G J Dekkers  1 , O W Akkerman  2   3 , J W C Alffenaar  4
Affiliations
Comment

Role of Therapeutic Drug Monitoring in Treatment Optimization in Tuberculosis and Diabetes Mellitus Comorbidity

B G J Dekkers et al. Antimicrob Agents Chemother. .
No abstract available

Keywords: azithromycin; diabetes mellitus; ethambutol; moxifloxacin; pharmacokinetics; pyrazinamide; rifampin; therapeutic drug monitoring; tuberculosis.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Serum concentrations over time for rifampin (A) and moxifloxacin (B).
See this image and copyright information in PMC

Comment on

References

    1. Alfarisi O, Mave V, Gaikwad S, Sahasradubhe T, Ramachandran G, Kumar H, Gupte N, Kulkarni V, Deshmukh S, Atre S, Raskar S, Lokhande R, Barthwal M, Kakrani A, Gupta A, Golub JE, Dooley KE. 2018. Effect of diabetes mellitus on the pharmacokinetics and pharmacodynamics of tuberculosis treatment. Antimicrob Agents Chemother 62:e01383-18. doi:10.1128/AAC.01383-18. - DOI - PMC - PubMed
    1. Ruslami R, Aarnoutse RE, Alisjahbana B, van der Ven AJAM, van Crevel R. 2010. Implications of the global increase of diabetes for tuberculosis control and patient care. Trop Med Int Health 15:1289–1299. doi:10.1111/j.1365-3156.2010.02625.x. - DOI - PubMed
    1. Dooley KE, Chaisson RE. 2009. Tuberculosis and diabetes mellitus: convergence of two epidemics. Lancet Infect Dis 9:737–746. doi:10.1016/S1473-3099(09)70282-8. - DOI - PMC - PubMed
    1. Alsultan A, Peloquin CA. 2014. Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs 74:839–854. doi:10.1007/s40265-014-0222-8. - DOI - PubMed
    1. Nijland HMJ, Ruslami R, Stalenhoef JE, Nelwan EJ, Alisjahbana B, Nelwan RHH, van der Ven AJAM, Danusantoso H, Aarnoutse RE, van Crevel R. 2006. Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes. Clin Infect Dis 43:848–854. doi:10.1086/507543. - DOI - PubMed